This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (13)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Treatment With Calcifediol

A. Michael Parfitt, MB, B Chir, FRCP, FRACP, FACP

Arch Intern Med. 1978;138(Suppl 5):874-881.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The synthetic analogues of vitamin D, either ergocalciferol or dihydrotachysterol, have been the mainstay of treatment for hypoparathyroidism (HP) for nearly 40 years.¹ The results have usually been unsatisfactory^2,3 owing mainly to serious defects in the available pharmaceutical preparations.^4-6 Many investigators have looked forward to the wider availability of the newer metabolites of vitamin D, but accurate appraisal of their therapeutic value requires comparison with results achieved with the older compounds formulated for optimum stability, absorption, and accuracy of dosage. Extensive previous experience with such preparations obtained from the Pharmacy of University College Hospital, London, and given to 33 patients with HP for a mean of 5 1/2 years led to several conclusions that are in conflict with current orthodox opinions.^2,3

First, most patients were rendered normocalcemic and asymptomatic and were able to lead normal lives with no disability. Second, the dose required in different patients . . . [Full Text PDF of this Article]

Author Affiliations
From the Bone and Mineral Research Laboratory and the Fifth Medical Division, Henry Ford Hospital, Detroit.

Footnotes
Read before the Upjohn Co, Kalamazoo, Mich, Nov 2, 1976.

Reprint requests to Bone and Mineral Research Laboratory, Henry Ford Hospital, Detroit, MI 48202 (Dr Parfitt).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?